16/03/2023 – Presentation of the AB Science Microtubule Destabilizer Agents platform webcast Download PDF Post navigationPreviousPrevious post:AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CETNextNext post:AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health CanadaRelated PostsAB Science webcast of March 4, 2024March 4, 2024AB Science webcast – Masitinib in Sickle Cell DiseaseNovember 30, 2023AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell diseaseNovember 28, 2023The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”November 27, 2023Revenues for the first half of 2023 and update on AB Science’s activitiesSeptember 29, 2023Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell diseaseNovember 28, 2023
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”November 27, 2023
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023
